Suppr超能文献

肺癌终末期患者疼痛治疗不足的趋势:中国城市医疗保险数据的分析。

Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China.

机构信息

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China.

出版信息

Thorac Cancer. 2024 Mar;15(9):693-701. doi: 10.1111/1759-7714.15240. Epub 2024 Feb 5.

Abstract

BACKGROUND

Cancer-related pain is one of the common priority symptoms in advanced lung cancer patients at the end-of-life (EOL). Alleviating pain is undoubtedly a critical component of palliative care in lung cancer. Our study was initiated to examined trends in opioid prescription-level outcomes as potential indicators of undertreated pain in China.

METHODS

This study used data on 1330 patients diagnosed with lung cancer of urban city medical insurance in China who died between 2014 and 2017. Opioid prescription-level outcomes were determined by annual trends of the proportion of patients filling an opioid prescription, the total dose of opioids filled by decedents, and morphine milligram equivalents per day (MMED) at the EOL (defined as the 60 days before death). We further analyzed monthly changes in the number of opioid prescriptions filled, MMED, and mean daily dose of opioids per prescription (MDDP) of the last 60 days of life by year at death and age, respectively.

RESULTS

A total of 959 patients with exact dates of death were included, with 432 cases (45.06%; 95% CI: 44.36%-45.77%) receiving at least one opioid prescription at the EOL. The declining trends were shown in the proportion of patients filling any opioid prescription, the total dose of opioids filled by decedents and MMED, with an annual decrease of 0.341% (p = 0.01), 104.23 mg (p = 0.011) and 2.84 mg (p = 0.014), respectively. Within the 31-60 days to the 0-30 days of life, the MMED declined 6.08 mg (95% CI: -7.14 to -5.03; p = 0.000351), while the number of opioid prescriptions rose 0.66 (95% CI: 0.160-1.16; p = 0.025). Like the MMED, the MDDP fell 4.11 mg (95% CI: -5.86 to -2.37; p = 0.005) within the last month before death compared to the previous month.

CONCLUSION

Terminal lung cancer populations in urban China have experienced reduced access to opioids at the EOL. The clinicians did not prescribe a satisfactory dose of opioids per prescription, while the patients suffered increasing pain in the last 30 days of life. Sufficient opioid analgesic administration should be advocated for lung cancer patients during the EOL period.

摘要

背景

癌症相关疼痛是晚期肺癌患者临终关怀的常见优先症状之一。缓解疼痛无疑是肺癌姑息治疗的重要组成部分。我们的研究旨在通过研究阿片类药物处方水平的变化趋势,作为中国治疗不足疼痛的潜在指标。

方法

本研究使用了在中国城市医疗保险中诊断为肺癌的 1330 名患者的数据,这些患者在 2014 年至 2017 年间死亡。阿片类药物处方水平的结果是通过每年填充阿片类药物处方的患者比例、死者服用的阿片类药物总量以及临终前(定义为死亡前 60 天)每天的吗啡毫克当量(MMED)来确定的。我们进一步分析了每年按死亡年龄和年龄划分的最后 60 天内每月阿片类药物处方数量、MMED 和每张处方平均每日阿片类药物剂量(MDDP)的变化。

结果

共纳入 959 名有确切死亡日期的患者,其中 432 例(45.06%;95%CI:44.36%-45.77%)在临终时至少接受了一种阿片类药物处方。患者使用任何阿片类药物处方的比例、死者服用的阿片类药物总量和 MMED 均呈下降趋势,年降幅分别为 0.341%(p=0.01)、104.23mg(p=0.011)和 2.84mg(p=0.014)。在生命的最后 31-60 天到生命的最后 0-30 天,MMED 下降了 6.08mg(95%CI:-7.14 至-5.03;p=0.000351),而阿片类药物处方数量增加了 0.66(95%CI:0.160-1.16;p=0.025)。与 MMED 一样,与前一个月相比,死亡前一个月 MDDP 下降了 4.11mg(95%CI:-5.86 至-2.37;p=0.005)。

结论

中国城市晚期肺癌人群在临终时获得的阿片类药物减少。临床医生没有开出每张处方足够的阿片类药物剂量,而患者在生命的最后 30 天内疼痛加剧。应提倡在临终期间为肺癌患者提供充足的阿片类药物镇痛治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ad8/10961226/411f0a1ef1e4/TCA-15-693-g004.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验